#BEGIN_DRUGCARD DB08806

# AHFS_Codes:
Not Available

# ATC_Codes:
A02BA06

# Absorption:
Well absorbed orally (80â€“90% bioavailability).

# Biotransformation:
Roxatidine acetate is rapidly metabolised to the primary, active desacetyl metabolite.

# Brand_Mixtures:
Not Available

# Brand_Names:
Roxit

# CAS_Registry_Number:
78628-28-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C19H28N2O4

# Chemical_IUPAC_Name:
({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}carbamoyl)methyl acetate

# Chemical_Structure:
Not Available

# Creation_Date:
2010-10-18 16:57:33 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

# Dosage_Forms:
Tablet, film coated	Oral
Tablet, film coated	Oral

# Drug_Category:
Anti-Ulcer Agents
Histamine H2 Antagonists

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Roxatidine acetate

# HET_ID:
Not Available

# Half_Life:
5-6 hours

# InChI_Identifier:
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

# InChI_Key:
InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N

# Indication:
For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08495

# LIMS_Drug_ID:
8813

# Mechanism_Of_Action:
The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

# Melting_Point:
145-146 for HCl salt

# Molecular_Weight_Avg:
348.4366

# Molecular_Weight_Mono:
348.204907394

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA165958424

# Pharmacology:
Roxatidine acetate suppresses the effect of histamine on the parietal cells of the stomach (H2-receptor antagonist). This suppressive action is dose-dependent. As a result, the production and secretion, particularly of gastric acid, are reduced. Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.

# Predicted_LogP_Hydrophobicity:
2.27

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
6.12e-02 g/l

# Primary_Accession_No:
DB08806

# Protein_Binding:
5-7%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Aceroxatidine
Pifatidine
Roxatidina
Roxatidine
Roxatidinum

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, mouse LD50: 1000 mg/kg

# Update_Date:
2013-02-08 16:27:17 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Roxatidine

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
20718616	Agrawal SS, Alvin Jose M: Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence. Syst Biol Reprod Med. 2010 Aug;56(4):286-91.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HRH2

# Drug_Target_1_GenBank_ID_Gene:
M64799

# Drug_Target_1_GenBank_ID_Protein:
184088

# Drug_Target_1_GeneCard_ID:
HRH2

# Drug_Target_1_Gene_Name:
HRH2

# Drug_Target_1_Gene_Sequence:
>1080 bp
ATGGCACCCAATGGCACAGCCTCTTCCTTTTGCCTGGACTCTACCGCATGCAAGATCACC
ATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGT
CTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTG
GCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGCCATCTACCAGCTG
TCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATG
CTCTGCACAGCCTCCATTCTTAACCTCTTCATGATCAGCCTCGACCGGTACTGCGCTGTC
ATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTC
TTAATTTGGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGC
AGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGTCCAGGTCAATGAA
GTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATC
ACCTACTACCGCATCTTCAAGGTCGCCCGGGATCAGGCCAAGAGGATCAATCACATTAGC
TCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATG
GGGGCCTTCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGA
GGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCTGGGCTATGCCAAC
TCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAA
CAGCTCTTCTGCTGCAGGCTGGCCAACCGCAACTCCCACAAAACTTCTCTGAGGTCCAAC
GCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTG
AAGCTCCAGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10371214	Murakami H, Sun-Wada GH, Matsumoto M, Nishi T, Wada Y, Futai M: Human histamine H2 receptor gene: multiple transcription initiation and tissue-specific expression. FEBS Lett. 1999 May 28;451(3):327-31.
1714721	Gantz I, Munzert G, Tashiro T, Schaffer M, Wang L, DelValle J, Yamada T: Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1386-92.
7755641	Nishi T, Koike T, Oka T, Maeda M, Futai M: Identification of the promoter region of the human histamine H2-receptor gene. Biochem Biophys Res Commun. 1995 May 16;210(2):616-23.
8817552	Orange PR, Heath PR, Wright SR, Pearson RC: Allelic variations of the human histamine H2 receptor gene. Neuroreport. 1996 May 17;7(7):1293-6.
9374694	Del Valle J, Gantz I: Novel insights into histamine H2 receptor biology. Am J Physiol. 1997 Nov;273(5 Pt 1):G987-96.

# Drug_Target_1_HGNC_ID:
HGNC:5183

# Drug_Target_1_HPRD_ID:
00816

# Drug_Target_1_ID:
124

# Drug_Target_1_Locus:
5q35.2

# Drug_Target_1_Molecular_Weight:
40099

# Drug_Target_1_Name:
Histamine H2 receptor

# Drug_Target_1_Number_of_Residues:
359

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Histamine H2 receptor
MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSL
AITDLLLGLLVLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAV
MDPLRYPVLVTPVRVAISLVLIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNE
VYGLVDGLVTFYLPLLIMCITYYRIFKVARDQAKRINHISSWKAATIREHKATVTLAAVM
GAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYANSALNPILYAALNRDFRTGYQ
QLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway

# Drug_Target_1_SwissProt_ID:
P25021

# Drug_Target_1_SwissProt_Name:
HRH2_HUMAN

# Drug_Target_1_Synonyms:
Gastric receptor I
H2R

# Drug_Target_1_Theoretical_pI:
9.39

# Drug_Target_1_Transmembrane_Regions:
23-44
58-81
93-114
135-159
181-204
235-258
268-289

#END_DRUGCARD DB08806
